{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:26:37Z","timestamp":1789244797279,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jhep.2021.08.025","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:48:00Z","timestamp":1630709280000},"page":"75-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-1577","authenticated-orcid":false,"given":"Raj","family":"Vuppalanchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6950-8174","authenticated-orcid":false,"given":"Nikolaos","family":"Pyrsopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1232-7986","authenticated-orcid":false,"given":"Andrew S.","family":"deLemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-6037","authenticated-orcid":false,"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-6474","authenticated-orcid":false,"given":"Aasim","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Ravinuthala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farheen","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Bainbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8545-6039","authenticated-orcid":false,"given":"Deven V.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga P.","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jhep.2021.08.025_bib1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.025_bib2","doi-asserted-by":"crossref","first-page":"11525","DOI":"10.1038\/s41598-019-47890-2","article-title":"Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort","volume":"9","author":"Marschall","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.025_bib3","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.025_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41575-019-0226-7","article-title":"Primary biliary cholangitis: pathogenesis and therapeutic opportunities","volume":"17","author":"Gulamhusein","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.08.025_bib6","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14627","article-title":"Primary Biliary Cholangitis management: controversies, perspectives, and daily practice implications from an expert panel","author":"Alvaro","year":"2020","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.jhep.2021.08.025_bib7","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/liv.14069","article-title":"Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus","volume":"39","author":"Hegade","year":"2019","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.jhep.2021.08.025_bib8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib9","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1572-0241.2000.01774.x","article-title":"Cholestatic liver diseases and health-related quality of life","volume":"95","author":"Younossi","year":"2000","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.025_bib10","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jhep.2020.03.043","article-title":"Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis","volume":"73","author":"Corpechot","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.025_bib11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2021.08.025_bib12","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.025_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2021.08.025_bib14","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16023","article-title":"Review article: pathophysiology and management of primary biliary cholangitis","volume":"52","author":"Leung","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2021.08.025_bib15","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.jhep.2021.08.025_bib16","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.14309\/ajg.0000000000000290","article-title":"Validation of risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangitis","volume":"114","author":"Efe","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2021.08.025_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000440759","article-title":"Surrogate endpoints for optimal therapeutic response to UDCA in primary biliary cholangitis","volume":"33","author":"van Buuren","year":"2015","journal-title":"Dig Dis"},{"issue":"7","key":"10.1016\/j.jhep.2021.08.025_bib18","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2021.08.025_bib19","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis","volume":"70","author":"Honda","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.025_bib20","doi-asserted-by":"crossref","first-page":"100191","DOI":"10.1016\/j.jhepr.2020.100191","article-title":"Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis","volume":"3","author":"Harms","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2021.08.025_bib21","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should Be bilirubin within the normal range and normalization of alkaline phosphatase","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.jhep.2021.08.025_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jhep.2021.08.025_bib23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-016-0616-x","article-title":"Obeticholic acid: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2021.08.025_bib24","first-page":"643","article-title":"Experimental pharmacological agents for the treatment of primary biliary cholangitis","volume":"12","author":"Floreani","year":"2020","journal-title":"J\u00a0Exp Pharmacol"},{"key":"10.1016\/j.jhep.2021.08.025_bib25","article-title":"Final data of the phase 2a intrepid study with EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist","volume":"72","author":"Kowdley","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.08.025_bib26","article-title":"The nonsteroidal farnesoid X receptor (FXR) agonist cilofexor improves liver biochemistry in patients with primary biliary cholangitis (PBC): a phase 2, randomized, placebo-controlled trial","volume":"70","author":"Kowdley","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib27","doi-asserted-by":"crossref","first-page":"100248","DOI":"10.1016\/j.jhepr.2021.100248","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D'Amato","year":"2021","journal-title":"JHEP Rep"},{"issue":"4","key":"10.1016\/j.jhep.2021.08.025_bib28","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.08.025_bib29","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-adds-boxed-warning-highlight-correct-dosing-ocaliva-obeticholic-acid-patients-rare-chronic-liver;Pages."},{"issue":"4","key":"10.1016\/j.jhep.2021.08.025_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J\u00a0Adv Pharm Technol Res"},{"issue":"9","key":"10.1016\/j.jhep.2021.08.025_bib31","first-page":"557","article-title":"Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA","volume":"110","author":"Duan","year":"2018","journal-title":"Rev Esp Enferm Dig"},{"issue":"9","key":"10.1016\/j.jhep.2021.08.025_bib32","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/liv.14165","article-title":"Additional fibrate treatment in UDCA-refractory PBC patients","volume":"39","author":"Chung","year":"2019","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib35","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/clpt.2011.124","article-title":"Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate","volume":"90","author":"Trottier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"23","key":"10.1016\/j.jhep.2021.08.025_bib36","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2021.08.025_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/1475-2840-11-140","article-title":"Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?","volume":"11","author":"Tenenbaum","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jhep.2021.08.025_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","author":"Tanaka","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2021.08.025_bib39","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/cpt.1930","article-title":"Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol","volume":"108","author":"Ghonem","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jhep.2021.08.025_bib40","first-page":"489","article-title":"Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials","volume":"32","author":"Agrawal","year":"2019","journal-title":"Ann Gastroenterol"},{"issue":"10","key":"10.1016\/j.jhep.2021.08.025_bib41","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.08.025_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A\u00a0randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","author":"Schattenberg","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2021.08.025_bib43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with\u00a0primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2021.08.025_bib44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/jm990554g","article-title":"The PPARs: from orphan receptors to drug discovery","volume":"43","author":"Willson","year":"2000","journal-title":"J\u00a0Med Chem"},{"issue":"3","key":"10.1016\/j.jhep.2021.08.025_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPARalpha\/gamma agonist with predominant PPARalpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"10.1016\/j.jhep.2021.08.025_bib46","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40261-013-0128-3","article-title":"Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects","volume":"33","author":"Jani","year":"2013","journal-title":"Clin Drug Investig"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/dia.2013.0253","volume":"16","author":"Jani","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jhep.2021.08.025_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of nonalcoholic fatty liver disease: a randomized controlled double-blind phase 2 trial","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.08.025_bib49","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","author":"de Vries","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.025_bib50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MCG.0000000000000029","article-title":"Metabolic syndrome associated with primary biliary cirrhosis","volume":"49","author":"Floreani","year":"2015","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00004836-200308000-00018","article-title":"Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis","volume":"37","author":"Siegel","year":"2003","journal-title":"J\u00a0Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhep.2021.08.025_bib52","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/hep4.1180","article-title":"Clinical application of the GLOBE and United Kingdom-primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis","volume":"2","author":"Carbone","year":"2018","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.jhep.2021.08.025_bib53","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gut.2005.079814","article-title":"Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis","volume":"55","author":"Allocca","year":"2006","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jhep.2021.08.025_bib54","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.1840150518","article-title":"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?","volume":"15","author":"Crippin","year":"1992","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib55","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF01307562","article-title":"Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis","volume":"38","author":"Propst","year":"1993","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib56","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","article-title":"Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review","volume":"194","author":"Sorokin","year":"2007","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jhep.2021.08.025_bib57","first-page":"119","article-title":"Risk of cardiovascular events in patients with primary biliary cholangitis - systematic review","volume":"6","author":"Suraweera","year":"2018","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.jhep.2021.08.025_bib58","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.12659\/MSM.916107","article-title":"The potential effects of diabetes mellitus on liver fibrosis in patients with primary biliary cholangitis","volume":"25","author":"Liu","year":"2019","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.jhep.2021.08.025_bib59","doi-asserted-by":"crossref","first-page":"21117","DOI":"10.1038\/s41598-020-78342-x","article-title":"Saroglitazar in\u00a0patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study","volume":"10","author":"Goyal","year":"2020","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.jhep.2021.08.025_bib60","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.08.025_bib61","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.14309\/00000434-200809001-00375","article-title":"Characteristics of patients with idiosyncratic drug induced liver injury (DILI) who receive systemic corticosteroids: initial results from the u. s. DILI network prospective study","volume":"103","author":"Chalasani","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhep.2021.08.025_bib62","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/pds.1210","article-title":"How can 'Hy's law' help the clinician?","volume":"15","author":"Senior","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.jhep.2021.08.025_bib63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy's law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jhep.2021.08.025_bib64","unstructured":"https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548607\/ (accessed on February 21, 2021)."},{"issue":"4","key":"10.1016\/j.jhep.2021.08.025_bib65","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/clpt.2013.122","article-title":"Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate","volume":"94","author":"Trottier","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.jhep.2021.08.025_bib66","doi-asserted-by":"crossref","first-page":"13975","DOI":"10.1074\/jbc.M300749200","article-title":"The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene","volume":"278","author":"Barbier","year":"2003","journal-title":"J\u00a0Biol Chem"},{"issue":"35","key":"10.1016\/j.jhep.2021.08.025_bib67","doi-asserted-by":"crossref","first-page":"32852","DOI":"10.1074\/jbc.M305361200","article-title":"Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme","volume":"278","author":"Barbier","year":"2003","journal-title":"J\u00a0Biol Chem"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821020237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821020237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:56Z","timestamp":1759175036000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821020237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0168827821020237"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.08.025","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}